Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of MM-121 plus paclitaxel vs paclitaxel in platinum-resistant/refractory advanced ovarian cancer
2011-003576-36Phase 2Completed
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of seribantumab in ovarian cancer (2 arms), sponsored by Merrimack Pharmaceuticals. Primary endpoint: Progression-free survival. Started Dec 2011; status: completed.
02
Drugs
seribantumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2011-003576-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003576-36.